Sunho Biologics

Sunho Biologics, Inc., (HKG: 2898) a clinical-stage biopharmaceutical company based in China specializing in biologic preparations for the treatment of cancer and autoimmune diseases, has successfully completed its initial public offering (IPO) on the Hong Kong Stock Exchange. The company issued 34,151,800 shares priced at HKD 13.5 per share, resulting…